logo-loader
RNS
Avacta Group PLC

Avacta Group PLC - Appointment of Nominated Adviser & TVR

RNS Number : 5119P
Avacta Group PLC
20 January 2026
 

 

Appointment of Nominated Adviser

Total Voting Rights Update

 

LONDON and PHILADELPHIA - January 20, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, announces the appointment of Strand Hanson Limited as the Company's Nominated Adviser, with immediate effect.  

 

Correction to Total Voting Rights

 

The Company's issued ordinary share capital is 440,415,495 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Additional information is disclosed below under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

-Ends-

 

For further information from Avacta, please contact:

 

Avacta Group plc

Christina Coughlin, Chief Executive Officer

https://avacta.com/

via ICR Healthcare





Strand Hanson Limited (Nominated Adviser)

James Harris / Chris Raggett / James Dance

 

 

 www.strandhanson.co.uk

 

Zeus (Broker)

James Hornigold / George Duxberry / Dominic King

 

 

www.zeuscapital.co.uk

ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 

avacta@consilium-comms.com

 

 

Investor Contact

Renee Leck

THRUST Strategic Communications

 

 

renee@thrustsc.com

 

Media Contact

Carly Scaduto

THRUST Strategic Communications

 carly@thrustsc.com

 

 

AIM Rule 17 Updates

 

In addition to the disclosures made in the announcement of Richard Hughes's appointment to the Board on 28 May 2025, Richard Hughes was:

 

appointed a director of Trafford Finance Limited on 28 October 2009, a company incorporated in England and Wales. The company was placed into administration on 21 April 2010 and was subsequently dissolved on 19 September 2013, with an estimated £5.4 million owed to creditors;

 

appointed a director of Procurasell International (Packaging) Ltd on 30 October 2007, a company incorporated in England and Wales. The company was placed into administration on 8 January 2009 and was subsequently dissolved on 23 September 2010, with approximately £0.1 million owing to creditors; and

 

appointed a director of Holyrood Leisure Limited on 26 April 2007, a company incorporated in England and Wales. The company was placed into administration on 28 June 2018 and was subsequently dissolved on 25 February 2020, with approximately £0.5 million owing to creditors.

 

About Avacta - www.avacta.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.

 

Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

 

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPFFFVLLDIALIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read